利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.016 秒)

    COMBINATION FOR USE IN A METHOD OF TREATING CANCER
    5.
    发明申请
    COMBINATION FOR USE IN A METHOD OF TREATING CANCER 审中-公开

    公开(公告)号：US20170216401A1

    公开(公告)日：2017-08-03

    申请号：US15126687

    申请日：2015-03-17

    申请人： Piotr JACHIMCZAK

    发明人： Piotr JACHIMCZAK ,  Achim AIGNER

    IPC分类号： A61K38/20 ,  A61K45/06 ,  A61K47/10 ,  A61K9/00 ,  A61K31/519 ,  A61K38/19

    CPC分类号： A61K38/2013 ,  A61K9/0019 ,  A61K31/519 ,  A61K38/193 ,  A61K45/06 ,  A61K47/10 ,  A61K2300/00

    摘要： The present invention refers to a combination of a TGF-beta inhibitor selected from the group consisting of an ALK-5 inhibitor, a neutralizing pan-anti-TGF-beta antibody, a neutralizing antibody against TGF-beta-1, or/and -2, or/and -3, a neutralizing anti-TGF-beta receptor type I or/and type II or/and type III antibody or binding fragments thereof with IL-2 and GM-CSF for use in a method of treating a malignant tumor in a patient. The invention is further directed to a pharmaceutical composition comprising the combination of the present invention, wherein the combination of compounds as well as the pharmaceutical composition are administered intratumorally. The combination as well as the pharmaceutical composition further comprise optionally an inhibitor of TGF-beta synthesis.

    Pharmaceutical composition
    6.
    发明申请
    Pharmaceutical composition 审中-公开
    药物组成

    公开(公告)号：US20070155685A1

    公开(公告)日：2007-07-05

    申请号：US10591048

    申请日：2005-02-28

    申请人： Karl-Hermann Schlingensiepen ,  Relmar Schlingensiepen ,  Piotr Jachimczak ,  Gerhard Stauder ,  Astrid Bischof ,  Michael Hafner ,  Tamara Egger

    发明人： Karl-Hermann Schlingensiepen ,  Relmar Schlingensiepen ,  Piotr Jachimczak ,  Gerhard Stauder ,  Astrid Bischof ,  Michael Hafner ,  Tamara Egger

    IPC分类号： A61K48/00 ,  C07H21/02

    CPC分类号： A61K31/713 ,  C12N15/1136 ,  C12N15/1137 ,  C12N15/1138 ,  C12N2310/11

    摘要： The present invention is related to pharmaceutical compositions for the inhibition of metastases and treatment of cancer such as bladder carcinoma, colon cancer, endometrial cancer, hepatocellular carcinoma, leukemia, lymphoma, melanoma, non-small cell lung cancer (NSCLC), ovarian cancer, pancreatic cancer, prostate cancer, soft tissue cancer, renal cancer, osteosarcoma, mesothelioma, myeloma multiple, bladder carcinoma and esophagcal cancer as well as the use of these pharmaceutical compositions for the treatment of said metastases and cancers. Another aspect of this invention are new antisense oligonucleotides inhibiting the formation of human interleukin 10 and their synthesis. A further aspect of this invention is the use IL-10 antisense oligonucleotides for the preparation of pharmaceutical compositions and for the treatment of cancer and metastases.

    摘要翻译： 本发明涉及用于抑制转移和治疗癌症的药物组合物，例如膀胱癌，结肠癌，子宫内膜癌，肝细胞癌，白血病，淋巴瘤，黑素瘤，非小细胞肺癌（NSCLC），卵巢癌， 胰腺癌，前列腺癌，软组织癌，肾癌，骨肉瘤，间皮瘤，骨髓瘤多发，膀胱癌和食道癌，以及这些药物组合物用于治疗所述转移和癌症的用途。 本发明的另一方面是抑制人白介素10的形成及其合成的新的反义寡核苷酸。 本发明的另一方面是使用IL-10反义寡核苷酸用于制备药物组合物和用于治疗癌症和转移瘤。